How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Virus Preparation Services Market
- By Virus Type: Adenovirus, Lentivirus, Retrovirus, Herpes Simplex Virus (HSV), Adeno-Associated Virus (AAV), Vaccinia Virus
- By Service Type: Virus Amplification, Virus Purification, Virus Titration, Virus Characterization, Custom Virus Engineering
- By End-Use Application: Gene Therapy, Vaccine Development, Oncolytic Virus Therapy, Diagnostic Research, Antiviral Drug Development
- By Virus Production Platform: Suspension Cell Culture, Adherent Cell Culture, Egg-Based Production, Bioreactor Systems, Perfusion Culture
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Adenovirus leads By Virus Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.171 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.179 →
Full report · locked preview
Everything inside the Virus Preparation Services Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Virus Type 6
Service Type 5
End-Use Application 5
Virus Production Platform 5
Companies profiled
Thermo Fisher Scientific
Charles River Laboratories
Cytiva (formerly GE Healthcare Life Sciences)
Virovek
ATCC (American Type Culture Collection)
Merck KGaA (MilliporeSigma)
Lonza Group
WuXi AppTec
Sartorius AG
BioReliance (a Merck company)
Creative Biolabs
ProSci Incorporated
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Charles River Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Cytiva (formerly GE Healthcare Life Sciences)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Virovek
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →ATCC (American Type Culture Collection)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Merck KGaA (MilliporeSigma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Lonza Group
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →WuXi AppTec
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Sartorius AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →BioReliance (a Merck company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Creative Biolabs
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →ProSci Incorporated
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Virongy
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Viral Vector Core at various academic institutions
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →GenScript Biotech Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$986.3M by 2033 · 9.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Adenovirus51.1
- Lentivirus10.7
- Retrovirus8.8
- Herpes Simplex Virus (HSV)8.9
- Adeno-Associated Virus (AAV)6.0
- Vaccinia Virus14.5
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$155.9M → $341.5M · 10.3%
Europe$108.7M → $213.9M · 8.8%
Asia Pacific$99.2M → $191.0M · 8.5%
Latin America$61.4M → $133.8M · 10.2%
Middle East and Africa$47.2M → $103.1M · 10.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.582026
9.592027
9.612028
9.632029
9.632030
9.652031
9.672032
9.672033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific21.7
- Charles River Laboratories12.6
- Cytiva (formerly GE Healthcare Life Sciences)6.3
- Virovek5.6
- ATCC (American Type Culture Collection)14.6
- Merck KGaA (MilliporeSigma)11.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Virus Type17.8%
Service Type17.0%
End-Use Application39.2%
Virus Production Platform26.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.7
- Europe21.7
- Asia Pacific19.4
- Latin America13.6
- Middle East and Africa10.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 74 | 76 | 81 | 97 | 78 | 80 | 81 |
| Charles River Laboratories | 92 | 71 | 88 | 72 | 82 | 79 | 81 |
| Cytiva (formerly GE Healthcare Life Sciences) | 84 | 78 | 80 | 63 | 62 | 77 | 74 |
| Virovek | 75 | 64 | 69 | 78 | 80 | 68 | 72 |
| ATCC (American Type Culture Collection) | 70 | 71 | 55 | 70 | 53 | 66 | 64 |
| Merck KGaA (MilliporeSigma) | 52 | 53 | 71 | 63 | 57 | 58 | 59 |
| Lonza Group | 43 | 52 | 53 | 63 | 41 | 47 | 50 |
| WuXi AppTec | 45 | 43 | 43 | 36 | 50 | 47 | 44 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Charles River Laboratories
- Cytiva (formerly GE Healthcare Life Sciences)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| Charles River Laboratories | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Cytiva (formerly GE Healthcare Life Sciences) | ✓ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Virovek | ◐ | ◐ | ◐ | ✓ | ◐ | ◐ |
| ATCC (American Type Culture Collection) | ✓ | ◐ | − | ◐ | − | − |
| Merck KGaA (MilliporeSigma) | ◐ | − | ◐ | ◐ | ◐ | − |
| Lonza Group | ◐ | ◐ | − | − | − | ◐ |
| WuXi AppTec | − | − | ◐ | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific81
2Charles River Laboratories81
3Cytiva (formerly GE Healthcare Life Sciences)74
4Virovek72
5ATCC (American Type Culture Collection)64
6Merck KGaA (MilliporeSigma)59
7Lonza Group50
8WuXi AppTec44
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificCharles River Laboratories
Challenger2
Strong scale, closing on the leaders.
Cytiva (formerly GE Healthcare Life Sciences)Virovek
Contender2
Focused players with pockets of strength.
ATCC (American Type Culture Collection)Merck KGaA (MilliporeSigma)
Niche2
Specialists in a single segment or region.
Lonza GroupWuXi AppTec
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Virus Type in North America, then scale across Virus Preparation Services Market — a $343M beachhead inside a $5.36B market.
Beachhead (SOM)$343Mobtainable near-term
Serviceable (SAM)$2.24Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Adenovirus
Best fit — highest urgency & budget in Virus Type.
Economic buyer76 fit
Lentivirus
Strong fit — clear ROI and a fast path to value.
End user65 fit
Retrovirus
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Virus Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Service Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End-Use Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve22%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Virus Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Virus Preparation Services Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified23%
Evaluation14%
Closed-won8%
$8.6KCAC
$35KLTV
4.1:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Virus Preparation Services Market is a durable-growth opportunity — $1.68B by 2033, compounding at 8.0%.
TAM · 2025$908Mtoday
TAM · 2033$1.68Bforecast
CAGR8.0%2027–2033
Cumulative$11.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.68BTotal addressable market
SAM$642MServiceable available market
SOM$115MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.0% CAGR
Demand compounds through 2033, outpacing GDP across Virus Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Virus Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.68BLarge & growingTAM by 2033 at 8.0% CAGR
$642MServiceable nowreachable with today’s model
$115MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.31BBear5.2% CAGR
$1.68BBase8.0% CAGR
$2.15BBull10.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Service Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Virus Preparation Services Market — a $12.1B market by 2033. Plan: grow share from 6.5% to 12.8%.
Market size · 2033$12.1Btotal addressable
Market CAGR11.4%2027–2033
Target share12.8%from 6.5% today
Revenue ambition$1.54Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 6.5% | 12.8% | Behind |
| Revenue | $835M | $1.54B | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 31.2% | 43.5% | Behind |
| Customer retention | 88.9% | 92.9% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Virus Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Service Type capability
A defensible second engine — invest in Service Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Virus Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Service Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $197M capacity & capability investment
- Greenlight bolt-on M&A in Service Type
- Authorise North America expansion plan
- Fund R&D program for Virus Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Virus Preparation Services Market conversation — a $5.73B market you can size, segment and defend in minutes.
Market size · 2033$5.73Btotal opportunity
Growth4.8%CAGR to 2033
Addressable buyers1,306+accounts in scope
Typical ROI6.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Virus Type
Goal Grow share in Virus Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.9×return on cost, year one
< 3 mopayback period
$44K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Thermo Fisher ScientificCharles River LaboratoriesCytiva (formerly GE Healthcare Life Sciences)VirovekATCC (American Type Culture Collection)Merck KGaA (MilliporeSigma)Lonza GroupWuXi AppTec+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Virus Preparation Services Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Virus Preparation Services Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Virus Nucleic Acid Isolation Kit Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportVirus-like Particle (VLP) Service Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportVirus-like Particles (VLPs) Vaccine Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View reportVirus-like Particle Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportVirus-Induced Asthma Treatment Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportVirus Filtration Solutions Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportVirus Filtration Membrane Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportVirus DNA Extraction Kit Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportVirus DNA and RNA Extraction Kit Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportVirus Diagnostics Market
Market size, share, segmentation and regional forecast.
$6.0B market · 2025 base year
View reportVirus Cryopreservation Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportVirus Clearance Validation Services Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.